Document is current

Article History

Received: 17 June 2025

Accepted: 5 January 2026

First Online: 2 March 2026

Change Date: 30 March 2026

Change Type: Update

Change Details: This paper was originally published under Creative Commons Attribution 4.0 International license, CC-BY-NC-ND, © The Author(s). It is now available under a Creative Commons Attribution 4.0 International license, CC-BY, © The Author(s). The error has been corrected in the online version of the article.

Competing interests

: S.B.H. has a contract with Eli Lilly and Company for clinical trials (institutional support). He has received honoraria for serving on the medical advisory boards of Tanita Corporation, Novo Nordisk, Lilly, Regeneron, Abbott and Medifast. He is also on the Data Safety Monitoring Committee for Novo Nordisk. L.J.A. has received research funding from Lilly, Novo Nordisk, Altimmune and Skye Bioscience. He is a consultant/advisory board member for Boehringer Ingelheim, Currax Pharmaceuticals, Lilly, Altimmune, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novo Nordisk, Pfizer, Veru Pharmaceuticals, Zealand Pharmaceuticals and Amgen. He has received payments or honoraria from Boehringer Ingelheim for his role as a consultant/advisory board member as well as from Skye Bioscience, Zealand Pharmaceuticals, Jamieson Wellness and Pfizer for lectures. He has received support for attending meetings and/or travel from Jamieson Wellness for his role as a consultant/advisory board member. He has patents pending with FlyteHealth and has served on the board of directors for FlyteHealth, Jamieson Wellness and ERX Pharmaceuticals. He holds equity interests in Jamieson Wellness, FlyteHealth, Kallyope, Mediflix, Metsera, MBX Bioscience, Syntis, Veru Pharmaceuticals and Skye Bioscience. P.M. has nothing to disclose. L.B.K. is a former employee and shareholder of Versanis Bio and a former employee of Lilly. He is an inventor or co-inventor on the following patents assigned to Versanis Bio: US20240368291A1 (ActRII antibody treatments), WO2024044782A1 (ActRII antibody fixed-dose treatments) and US20240325530A1 (combination therapies). L.A.C. is an employee and shareholder of Lilly. She is a former employee of Versanis Bio with equity holdings. She also has a pending patent (PAT058683-US-PSP). K.D. is an employee and shareholder of Lilly. She is also a former employee of Versanis Bio with equity holdings. L.M. is a former consultant to Versanis Bio with equity holdings. She is now a consultant to Lilly. S.S. was a former consultant to Versanis Bio and is now a consultant to Lilly. X.L. is an employee and stockholder of Lilly. K.M.A. is an employee and shareholder of Lilly. He is also a former employee of Versanis Bio with equity holdings.